← FDA DRUG APPROVALS

FDA NDA · NDA020005

CARDENE SR

Sponsor: CHIESI

APPLICATION
NDA020005
TYPE
NDA
ORIGINAL APPROVAL
1992-02-21
LATEST ACTION
2016-08-29
ROUTE
ORAL
DOSAGE FORM
CAPSULE, EXTENDED RELEASE
MARKETING STATUS
Discontinued

Products

CARDENE SR · ReferenceDiscontinued
NICARDIPINE HYDROCHLORIDE 60MG **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons** · CAPSULE, EXTENDED RELEASE · ORAL
CARDENE SR · ReferenceDiscontinued
NICARDIPINE HYDROCHLORIDE 30MG **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons** · CAPSULE, EXTENDED RELEASE · ORAL
CARDENE SR · ReferenceDiscontinued
NICARDIPINE HYDROCHLORIDE 45MG **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons** · CAPSULE, EXTENDED RELEASE · ORAL

Approval history

2016-08-29Labeling · Supplement 14 · standardLetterAP
2002-07-30Manufacturing (CMC) · Supplement 7 · standardAP
2001-11-09Manufacturing (CMC) · Supplement 6 · standardAP
1999-09-29Labeling · Supplement 5 · standardAP
1997-01-07Manufacturing (CMC) · Supplement 4 · standardAP
1996-02-22Manufacturing (CMC) · Supplement 3 · standardAP
1993-11-04Labeling · Supplement 2 · standardAP
1992-11-20Labeling · Supplement 1 · standardAP
1992-02-21Type 3 - New Dosage Form · Original · standardAP
VIEW ON DRUGS@FDA ↗

Related on SPEQ

Pharma industryGMP disciplineFDA drug shortagesFDA enforcement & recalls

Source: FDA Drugs@FDA. SPEQ is not affiliated with the FDA; this is a reference view of public FDA data, not medical, legal, or regulatory advice.

Weekly Briefing

Get the Weekly GxP Briefing

Curated regulatory intelligence — enforcement, recalls, guidance, and quality signals — in one practitioner-grade email each week. Free.

Read a past issue →